News from the FDA/CDC

FDA approves Amphastar Pharma’s nasal spray for opioid overdose


(Reuters) – Amphastar Pharmaceuticals said on March 6 the Food and Drug Administration had approved its nasal spray for emergency treatment of known or suspected opioid overdose.

The company’s naloxone hydrochloride nasal spray can be delivered in one spray by intranasal administration – delivering 4 mg of the drug in adults and pediatric patients – for an initial dosing, according to the FDA label. The regulator’s approval allows its use only when prescribed.

The nod comes at a time when the agency is reviewing applications to also allow over-the-counter use of some naloxone-based drugs, including an application for Emergent Biosolutions’ Narcan.

Late in 2022, the health regulator had said naloxone might be safe and effective for over-the-counter use in some forms, potentially paving the way for its use federally and encouraging more manufacturers to seek approval for prescription-free use.

More than 106,000 people died in the United States from drug-involved overdose in 2021, according to government data.

Reuters Health Information © 2023

Recommended Reading

Docs struggle to keep up with the flood of new medical knowledge. Here’s advice
MDedge Psychiatry
NP-PA turf fights: Where the relationship can improve
MDedge Psychiatry
Specialty and age may contribute to suicidal thoughts among physicians
MDedge Psychiatry
Telehealth doctor indicted on health care fraud, opioid distribution charges
MDedge Psychiatry
Who can sue docs for wrongful death? Some states are trying to expand that group
MDedge Psychiatry